Abeona Therapeutics faces securities fraud probe after Q2 revenue recognition issues hit stock.

Pomerantz LLP is investigating Abeona Therapeutics for potential securities fraud following the company's Q2 2026 financial report. Abeona disclosed that although five patients were treated with its therapy ZEVASKYN, only four treatments qualified for revenue recognition due to one batch not meeting minimum requirements. This revelation caused Abeona's stock to drop nearly 15% on August 13, 2026. The investigation will determine if Abeona and its executives engaged in unlawful business practices, impacting investors' trust and stock value.